Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-5nwft Total loading time: 0 Render date: 2024-05-26T07:24:22.872Z Has data issue: false hasContentIssue false

24 - Amyotrophic Lateral Sclerosis

from Section 6

Published online by Cambridge University Press:  05 May 2012

Bernard Ravina
Affiliation:
Biogen Idec., Cambridge, MA
Jeffrey Cummings
Affiliation:
Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas
Michael McDermott
Affiliation:
University of Rochester
R. Michael Poole
Affiliation:
AstraZeneca PLC, Waltham, MA, US
Get access

Summary

This chapter discusses preclinical disease models, biomarkers, clinical trial design options, and challenges to the conduct of Amyotrophic Lateral Sclerosis (ALS) clinical trials. The primary goals of most clinical trials in ALS are to slow disease progression as measured either by function or survival. Functional scales include measures of strength, pulmonary function, and a questionnaire called the ALS functional rating scale-revised (ALSFRS-R). The incidence of ALS is approximately 2/100,000/year. Fifty percent of people with ALS die within 3 years of onset of symptoms and 90% die within 5 years. The statistical techniques used in ALS clinical trials depend on the outcome measure. The largest challenge in clinical trials that use ALSFRS-R or other longitudinal outcomes measures is missing data. Development of a sensitive and specific diagnostic biomarker for ALS can help early accurate diagnosis and enrollment in clinical trials, which allows earlier initiation of potential therapies.
Type
Chapter
Information
Clinical Trials in Neurology
Design, Conduct, Analysis
, pp. 273 - 283
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×